According to court documents released on Thursday,PfizerA payment of $345 million has been agreed to settle the price fraud lawsuit filed by consumers for the epinephrine injection pen EpiPen.

A filing in the Kansas City federal court revealed this proposed class-action settlement agreement. The agreement needs to be approved by a judge.

Plaintiffs' attorney Paul Geller (Paul Geller) said they are “happy that Pfizer has resolved the portion of the EpiPens pricing class action lawsuit relating to it.”

EpiPen is a handheld device that can treat life-threatening allergic reactions by automatically injecting a dose of epinephrine.

In 2016, the one with marketing and distribution rights for EpiPensMylan Pharmaceuticals(Mylan) raised the price of a pair of EpiPens from $100 in 2008 to $600, making it the center of an ongoing debate over the high cost of drugs in the US, sparking public outcry and sparking this class-action lawsuit.

The lawsuit alleges that Mylan and Pfizer, which manufactures EpiPens for Mylan, engaged in anti-competitive behavior that allowed them to maintain a monopoly on the equipment market and its earnings revenue.